National Institute of Nursing Research; Notice of Meeting, 21434 [05-8288]
Download as PDF
<![CDATA[
21434
Federal Register / Vol. 70, No. 79 / Tuesday, April 26, 2005 / Notices
The discovery should also lead to the
development of novel pharmaceutical
products and methods for treating BHD
skin lesions using creams containing the
BHD gene product, folliculin. Such
products and methods of treatment are
expected to reduce the size and
appearance of the benign hair follicle
tumors.
The disclosed technology will provide
new and exciting methodologies to
correctly diagnose BHD syndrome and
should lead to the development of novel
pharmaceutical reagents for treatment of
BHD skin lesions as well as other skin
diseases.
This research is also described in: MB
Warren et al., Mod Pathol. (2004 Aug)
17(8):998–1011; ML Nickerson et al.,
Cancer Cell (2002 Aug) 2(2):157–164; B
Zbar et al., Cancer Epidem. Bio. Prev.
(2002 Apr) 11(4):393–400; LS Schmidt
et al., Am. J. Hum. Genet. (2001 Oct)
69(4):876–882; Toro et al., Arch.
Dermatol. (1999 Oct) 135(10): 1195–
1202.
In addition to licensing, the
technology is available for further
development through collaborative
research opportunities with the
inventors.
Compositions Of Transforming Growth
Factor Beta (TGF-beta) Which Promotes
Wound Healing and Methods for Their
Use
Michael Sporn et al. (NCI).
U.S. Patent No. 5,104,977, granted April
14, 1992, entitled ‘‘Purified
Transforming Growth Factor Beta’’
(DHHS Ref. No. E–070–1982/2-US–
05);
U.S. Patent No. 5,656,587, granted
August 12, 1997, entitled ‘‘Promotion
Of Cell Proliferation By Use Of
Transforming Growth Factor Beta
(TGF-Beta)’’ (DHHS Ref. No. E–070–
1982/2-US–07); and
U.S. Patent No. 5,705,477, granted
January 6, 1998, entitled
‘‘Compositions Of Transforming
Growth Factor Beta (TGF-Beta) Which
Promotes Wound Healing And
Methods For Their Use’’ (DHHS Ref.
No. E–070–1982/2-US–08).
Licensing Contact: Jesse S. Kindra; 301/
435–5559; kindraj@mail.nih.gov.
There is a continuing need for the
promotion of rapid cell proliferation at
the site of wounds, burns, diabetic and
decubitus ulcers, and other traumata.
Prior to this invention, a number of
‘‘growth factors’’ were known to
promote the rapid growth of cells. None
of these growth factors, however, had
been found to be pharmaceutically
acceptable agents for the acceleration of
wound healing.
VerDate jul<14>2003
11:52 Apr 25, 2005
Jkt 205001
This invention relates to compositions
of Transforming Growth Factor beta
(TGF-beta) which promote repair of
tissue, particularly fibroblast cells, in
animals and human beings. This
invention also relates to a method of
treating wounds by the topical or
systemic administration of the
compositions. The discovery of this
invention initiated a worldwide field of
research aimed at the characterization
and development of TGF-beta in wound
healing and disease. It is now known
that TGF-beta’s role in wound healing is
complex. Its diverse effects on the many
individual participating cell types in a
wound are integrated into a specific
temporal sequence of events within a
defined tissue architecture. In addition
to its many roles in wound healing,
TGF-beta is also implicated in the
pathogenesis of diseases such as
autoimmune disease, fibrosis, and
cancer.
Current research in TGF-beta biology
is leading to the development of novel
wound healing and disease therapies
related to the growth factor and its
signaling pathways.
Dated: April 18, 2005.
Steven M. Ferguson,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. 05–8287 Filed 4–25–05; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Nursing Research;
Notice of Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. appendix 2), notice
is hereby given of a meeting of the
National Advisory Council for Nursing
Research.
The meeting will be open to the
public as indicated below, with
attendance limited to space available.
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications
and/or contract proposals and the
discussions could disclose confidential
trade secrets or commercial property
PO 00000
Frm 00046
Fmt 4703
Sfmt 4703
such as patentable material, and
personal information concerning
individuals associated with the grant
applications and/or contract proposals,
the disclosure of which would
constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Advisory
Council for Nursing Research.
Date: May 17–18, 2005.
Open: May 17, 2005, 1 p.m. to 5 p.m.
Agenda: For discussion of program issues
and initiatives.
Place: National Institutes of Health,
Building 31, 31 Center Drive, Bethesda, MD
20892.
Closed: May 18, 2005, 9 a.m. to 2 p.m.
Agenda: To review and evaluate grant
applications and/or proposals.
Place: National Institutes of Health,
Building 31, 31 Center Drive, Bethesda, MD
20892.
Contact Person: Mary E. Kerr, FAAN, RN,
PhD, Deputy Director, National Institute of
Nursing, National Institutes of Health, 31
Center Drive, Room 5B–05, Bethesda, MD
20892–2178, 301/496–8230,
kerrme@mail.nih.gov.
Any member of the public interested in
presenting oral comments to the committee
may notify the Contact Person listed on this
notice at least 10 days in advance of the
meeting. Interested individuals and
representatives of organizations may submit
a letter of intent, a brief description of the
organization represented, and a short
description of the oral presentation. Only one
representative of an organization may be
allowed to present oral comments and if
accepted by the committee, presentations
may be limited to five minutes. Both printed
and electronic copies are requested for the
record. In addition, any interested person
may file written comments with the
committee by forwarding their statement to
the Contact Person listed on this notice. The
statement should include the name, address,
telephone number and when applicable, the
business or professional affiliation of the
interested person.
Information is also available on the
Institute’s/Center’s home page: https://
www.nih.gov/ninr/a_advisory.html, where an
agenda and any additional information for
the meeting will be posted when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.361, Nursing Research,
National Institutes of Health, HHS)
Dated: April 15, 2005.
Anna Snouffer,
Acting Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 05–8288 Filed 4–25–05; 8:45 am]
BILLING CODE 4140–01–M
E:\FR\FM\26APN1.SGM
26APN1
]]>Agencies
[Federal Register Volume 70, Number 79 (Tuesday, April 26, 2005)]
[Notices]
[Page 21434]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-8288]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Nursing Research; Notice of Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. appendix 2), notice is hereby given of a meeting of
the National Advisory Council for Nursing Research.
The meeting will be open to the public as indicated below, with
attendance limited to space available. Individuals who plan to attend
and need special assistance, such as sign language interpretation or
other reasonable accommodations, should notify the Contact Person
listed below in advance of the meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and/or contract proposals
and the discussions could disclose confidential trade secrets or
commercial property such as patentable material, and personal
information concerning individuals associated with the grant
applications and/or contract proposals, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Advisory Council for Nursing
Research.
Date: May 17-18, 2005.
Open: May 17, 2005, 1 p.m. to 5 p.m.
Agenda: For discussion of program issues and initiatives.
Place: National Institutes of Health, Building 31, 31 Center
Drive, Bethesda, MD 20892.
Closed: May 18, 2005, 9 a.m. to 2 p.m.
Agenda: To review and evaluate grant applications and/or
proposals.
Place: National Institutes of Health, Building 31, 31 Center
Drive, Bethesda, MD 20892.
Contact Person: Mary E. Kerr, FAAN, RN, PhD, Deputy Director,
National Institute of Nursing, National Institutes of Health, 31
Center Drive, Room 5B-05, Bethesda, MD 20892-2178, 301/496-8230,
kerrme@mail.nih.gov.
Any member of the public interested in presenting oral comments
to the committee may notify the Contact Person listed on this notice
at least 10 days in advance of the meeting. Interested individuals
and representatives of organizations may submit a letter of intent,
a brief description of the organization represented, and a short
description of the oral presentation. Only one representative of an
organization may be allowed to present oral comments and if accepted
by the committee, presentations may be limited to five minutes. Both
printed and electronic copies are requested for the record. In
addition, any interested person may file written comments with the
committee by forwarding their statement to the Contact Person listed
on this notice. The statement should include the name, address,
telephone number and when applicable, the business or professional
affiliation of the interested person.
Information is also available on the Institute's/Center's home
page: https://www.nih.gov/ninr/a_advisory.html, where an agenda and
any additional information for the meeting will be posted when
available.
(Catalogue of Federal Domestic Assistance Program Nos. 93.361,
Nursing Research, National Institutes of Health, HHS)
Dated: April 15, 2005.
Anna Snouffer,
Acting Director, Office of Federal Advisory Committee Policy.
[FR Doc. 05-8288 Filed 4-25-05; 8:45 am]
BILLING CODE 4140-01-M
